- RecruitingPHASE2
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
This study is looking into a new treatment called INCB123667 for women with ovarian cancer that has come back or grown despite platinum-based chemotherapy. Researchers want to see if this treatment is safe and effective, especially for cancers with high levels of a protein called Cyclin E1.
For: Ovarian CancerUnited States · Australia · Belgium - RecruitingPHASE3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
This study compares a new medicine, INCB123667, with standard chemotherapy for women with ovarian cancer that has grown despite platinum-based treatment and shows specific genetic changes. It aims to see if the new drug works better than current options.
For: Ovarian CancerUnited States · Australia · Belgium